Fortress Biotech, Inc. (NASDAQ:FBIOP) Short Interest Down 78.4% in June

Fortress Biotech, Inc. (NASDAQ:FBIOP) saw a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 1,100 shares, a decline of 78.4% from the May 31st total of 5,100 shares. Based on an average daily trading volume, of 10,300 shares, the days-to-cover ratio is currently 0.1 days.

Fortress Biotech Stock Down 0.8 %

Shares of NASDAQ FBIOP traded down $0.13 during mid-day trading on Thursday, hitting $15.80. The stock had a trading volume of 2,604 shares, compared to its average volume of 11,322. Fortress Biotech has a 1 year low of $6.40 and a 1 year high of $18.73. The business has a 50 day moving average price of $15.85 and a two-hundred day moving average price of $14.99.

Fortress Biotech Announces Dividend

The business also recently disclosed a monthly dividend, which will be paid on Sunday, June 30th. Shareholders of record on Saturday, June 15th will be given a dividend of $0.1953 per share. This represents a $2.34 dividend on an annualized basis and a yield of 14.83%. The ex-dividend date of this dividend is Friday, June 14th.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.